🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study was originally designed as a Phase III randomized, double blind,...
Status
Terminated
Location
Novartis Investigative Site
Start Date
2005-12-13
Trial ID
NCT00272987
Treatments Being Tested
A study to compare the safety and efficacy of an aromatase inhibitor in com...
Status
Completed
Location
Novartis Investigative Site
Start Date
2011-05-05
Trial ID
NCT01160211
Treatments Being Tested
This is a Phase III, randomized, multicenter, international, 2-arm, open-la...
Status
Completed
Location
Multiple Locations
Start Date
2009-02
Trial ID
NCT00829166
Treatments Being Tested
The goal of this clinical research study is to find the highest tolerable d...
Status
Completed
Location
UT MD Anderson Cancer Center
Start Date
2007-06
Trial ID
NCT00495872
Treatments Being Tested
This study is an open-label, dose-escalation study of MM-111 with five diff...
Status
Completed
Location
Rocky Mountain Cancer Centers
Start Date
2011-01
Trial ID
NCT01304784
This study is being conducted to compare the efficacy and safety of pazopan...
Status
Completed
Location
GSK Investigational Site
Start Date
2006-07
Trial ID
NCT00347919
* Lapatinib in combination with capecitabine has been approved for the trea...
Status
Terminated
Location
Klinikum der Otto-v.-Guericke-Universität Frauenklinik
Start Date
2012-02
Trial ID
NCT01534455
Treatments Being Tested
The purpose of this study is to estimate the clinical benefit of lapatinib ...
Status
Withdrawn
Location
Charite Campus Mitte II. Medizinische Klinik Hämatologie und Onkologie
Start Date
2013-09
Trial ID
NCT01985893
Treatments Being Tested
This is a Phase III, randomized, multicenter, two-arm, open-label study des...
Status
Completed
Location
Beijing Hospital
Start Date
2017-04-24
Trial ID
NCT03084939
Treatments Being Tested
Diarrhoea is the most commonly reported adverse event (AE) associated with ...
Status
Terminated
Location
Novartis Investigative Site
Start Date
2014-12-17
Trial ID
NCT02294786
Treatments Being Tested